Clinical Trial Update: Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency [Phase 3]

View source ↗

Summary

A Phase 3 trial of tadekinig alfa for NLRC4-associated macrophage activation syndrome (NLRC4-MAS) and XIAP deficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nlrc4-associated Macrophage Activation Syndrome
• Xiap Deficiency

Drugs mentioned

• Tadekinig Alfa (tadekinig alfa)

Snippet

Sponsor: AB2 Bio Ltd. | Conditions: NLRC4-MAS, XIAP Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2025-07-02